AGA2115 is named as an intervention in 2 current clinical trials in our UK, USA, France, Netherlands, Denmark, Canada, Mexico, Australia and China registers. 2 are recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Angitia Incorporated Limited (1). The most-studied condition is Osteogenesis Imperfecta (OI). The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588 · ClinicalTrials.gov ↗ · Osteogenesis Imperfecta (OI)
|
Phase 2 | Recruiting | Angitia Incorporated Limited | UK, USA, France, Netherlands, Denmark, Canada, Mexico, Australia |
|
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
NCT07557446 · ClinicalTrials.gov ↗ · Osteogenesis Imperfecta (OI)
|
Phase 2 | Recruiting | Angitia Biopharmaceuticals Guangzhou Limited | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing AGA2115. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)
2025-522951-24-00 · CTIS ↗ · Musculoskeletal Diseases
|
Phase 2 | Authorised | Angitia Inc. Ltd | Netherlands, France, Denmark |
| Lead sponsor | Trials |
|---|---|
| Angitia Incorporated Limited | 1 |
| Angitia Biopharmaceuticals Guangzhou Limited | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our UK, USA, France, Netherlands, Denmark, Canada, Mexico, Australia and China registers name AGA2115 as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in France, 1 with sites in Netherlands, 1 with sites in Denmark, 1 with sites in Canada, 1 with sites in Mexico, 1 with sites in Australia and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Angitia Incorporated Limited (1) and Angitia Biopharmaceuticals Guangzhou Limited (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how AGA2115 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how AGA2115 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AGA2115 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.